Do You Think Medicines Can Be Prescribed in a More Eco-directed, Greener Way? A Qualitative Study Based on Public and Prescriber Focus Groups on the Impact of Pharmaceuticals in Scotland's Water Environment

Overview

Journal BMJ Open

Date 2025 Jan 20

PMID 39832959

Authors

Lydia Niemi

Claire Anderson

Naoko Arakawa

Mark Taggart

Stuart Gibb

Sharon Pfleger

Affiliations

Soon will be listed here.

Abstract

Objectives: This qualitative study explored public and prescriber awareness of pharmaceutical pollution in the water environment and eco-directed sustainable prescribing (EDSP) as a mitigation strategy to reduce the environmental impact of prescribing in Scotland.

Design: Focus groups explored prescriber and public perceptions of the topic. Common questions were asked through semistructured facilitation. Focus groups were digitally recorded and transcribed verbatim using an artificial intelligence system, then anonymised and thematically analysed using NVivo software. Data were iteratively analysed using the one sheet of paper technique.

Setting: Public focus groups were held in-person (Inverness, Scotland, April 2023), and prescriber focus groups were held virtually (MS Teams, August 2023).

Participants: Nine public representatives and 17 NHS Scotland prescribers participated in one of four focus groups. Purposive and opportunistic sampling approaches were used to recruit participants through social media and other channels (ie, community groups, professional emails, general practitioner and hospital flyers). Prescriber representatives registered interest through an online survey to gather information about their professional background. Responses were reviewed to ensure representation of a mixture of medical backgrounds, experience, sectors and health boards.

Results: There is growing awareness among the public and healthcare professionals of pharmaceutical pollution in the environment, but further education is required on the drivers, potential effects and possible interventions. Suggestions for more sustainable healthcare included public health awareness campaigns, better provision for pharmacy take-back schemes, clear medicine/packaging labelling, regular medicines reviews and more considered patient-centred care. From the prescriber perspective, EDSP resonated well with current sustainability initiatives (eg, Realistic Medicine, switching to dry-powder inhalers), but barriers to EDSP included lack of knowledge, confidence, time and resources to implement changes. Although the public representatives were generally open to the concept of EDSP, this decision required weighing pros/cons considering personal health choices, information accessibility and transparency, and trust in and time with prescribers.

Conclusions: This study identified new insights from prescribers and the public related to the concept of, and barriers to, EDSP in Scotland, as well as perspectives regarding knowledge support tools and information communication. Cross-sector and transdisciplinary collaborative approaches are needed to address the challenges identified here. Nonetheless, EDSP merits further exploration in developing more sustainable, appropriate and effective healthcare which contributes to improved public and planetary health.

References

Gould S, Winter M, Norton W, Tyler C . The potential for adverse effects in fish exposed to antidepressants in the aquatic environment. Environ Sci Technol. 2021; 55(24):16299-16312. DOI: 10.1021/acs.est.1c04724. View

Lister A, Regan C, Van Zwol J, Van Der Kraak G . Inhibition of egg production in zebrafish by fluoxetine and municipal effluents: a mechanistic evaluation. Aquat Toxicol. 2009; 95(4):320-9. DOI: 10.1016/j.aquatox.2009.04.011. View

Wilkinson J, Boxall A, Kolpin D, Leung K, Lai R, Galban-Malagon C . Pharmaceutical pollution of the world's rivers. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872717. DOI: 10.1073/pnas.2113947119. View

Mann C, Anderson C, Boyd M, Karsan Y, Emerson T . Perspectives of pharmacists in general practice from qualitative focus groups with patients during a pilot study. BJGP Open. 2021; 6(2). PMC: 9447328. DOI: 10.3399/BJGPO.2021.0112. View

Daughton C . Eco-directed sustainable prescribing: feasibility for reducing water contamination by drugs. Sci Total Environ. 2014; 493:392-404. DOI: 10.1016/j.scitotenv.2014.06.013. View

Agerstrand M, Arinaitwe K, Backhaus T, Barra R, Diamond M, Grimalt J . Key Principles for the Intergovernmental Science-Policy Panel on Chemicals and Waste. Environ Sci Technol. 2023; 57(6):2205-2208. PMC: 9933528. DOI: 10.1021/acs.est.2c08283. View

Vestel J, Caldwell D, Tell J, Constantine L, Haner A, Hellstern J . Default predicted no-effect target concentrations for antibiotics in the absence of data for the protection against antibiotic resistance and environmental toxicity. Integr Environ Assess Manag. 2021; 18(4):863-867. PMC: 9302680. DOI: 10.1002/ieam.4560. View

Dohle S, Campbell V, Arvai J . Consumer-perceived risks and choices about pharmaceuticals in the environment: a cross-sectional study. Environ Health. 2013; 12:45. PMC: 3680168. DOI: 10.1186/1476-069X-12-45. View

Smale E, van der Werff I, van den Bemt B, Bekker C . How to engage healthcare providers in preventing medication waste through individualized prescribing and dispensing: A qualitative study. Res Social Adm Pharm. 2023; 19(10):1365-1371. DOI: 10.1016/j.sapharm.2023.06.004. View

10.

Toolan M, Walpole S, Shah K, Kenny J, Jonsson P, Crabb N . Environmental impact assessment in health technology assessment: principles, approaches, and challenges. Int J Technol Assess Health Care. 2023; 39(1):e13. PMC: 11570021. DOI: 10.1017/S0266462323000041. View

11.

der Beek T, Weber F, Bergmann A, Hickmann S, Ebert I, Hein A . Pharmaceuticals in the environment--Global occurrences and perspectives. Environ Toxicol Chem. 2015; 35(4):823-35. DOI: 10.1002/etc.3339. View

12.

Niemi L, Taggart M, Boyd K, Zhang Z, Gaffney P, Pfleger S . Assessing hospital impact on pharmaceutical levels in a rural 'source-to-sink' water system. Sci Total Environ. 2020; 737:139618. DOI: 10.1016/j.scitotenv.2020.139618. View

13.

Gardner M, Comber S, Ellor B . Summary of data from the UKWIR chemical investigations programme and a comparison of data from the past ten years' monitoring of effluent quality. Sci Total Environ. 2022; 832:155041. DOI: 10.1016/j.scitotenv.2022.155041. View

14.

Linder E, Wettermark B, Ovesjo M, Kalvemark Sporrong S, Ramstrom H . Knowledge support for environmental information on pharmaceuticals: experiences among Swedish Drug and Therapeutics Committees. BMC Health Serv Res. 2023; 23(1):618. PMC: 10259041. DOI: 10.1186/s12913-023-09646-7. View

15.

Thornber K, Adshead F, Balayannis A, Brazier R, Brown R, Comber S . First, do no harm: time for a systems approach to address the problem of health-care-derived pharmaceutical pollution. Lancet Planet Health. 2022; 6(12):e935-e937. DOI: 10.1016/S2542-5196(22)00309-6. View

16.

Redvers N, Wright K, Hartmann-Boyce J, Tonkin-Crine S . Physicians' views of patient-planetary health co-benefit prescribing: a mixed methods systematic review. Lancet Planet Health. 2023; 7(5):e407-e417. DOI: 10.1016/S2542-5196(23)00050-5. View

17.

Bound J, Kitsou K, Voulvoulis N . Household disposal of pharmaceuticals and perception of risk to the environment. Environ Toxicol Pharmacol. 2011; 21(3):301-7. DOI: 10.1016/j.etap.2005.09.006. View

18.

Holm G, Snape J, Murray-Smith R, Talbot J, Taylor D, Sorme P . Implementing ecopharmacovigilance in practice: challenges and potential opportunities. Drug Saf. 2013; 36(7):533-46. PMC: 3691479. DOI: 10.1007/s40264-013-0049-3. View

19.

Linder E, Villen J, Nekoro M, Wettermark B, Kalvemark Sporrong S . Stakeholders' perspectives and use of web-based knowledge support for environmental information on pharmaceuticals. Explor Res Clin Soc Pharm. 2023; 11:100303. PMC: 10387601. DOI: 10.1016/j.rcsop.2023.100303. View

20.

Gibson Smith K, Booth J, Stewart D, Pfleger S, McIver L, Maclure K . Supporting shared decision-making and people's understanding of medicines: An exploration of the acceptability and comprehensibility of patient information. Pharm Pract (Granada). 2018; 15(4):1082. PMC: 5742002. DOI: 10.18549/PharmPract.2017.04.1082. View